

May 14, 2019

Edward Kaye  
Chief Executive Officer  
Stoke Therapeutics, Inc.  
45 Wiggins Avenue  
Bedford, MA 01730

Re: Stoke Therapeutics, Inc.  
Amendment No. 1 to Draft Registration Statement on Form S-1  
Submitted April 30, 2019  
CIK No. 0001623526

Dear Dr. Kaye:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our April 17, 2019 letter.

Amendment No. 1 to Draft Registration Statement on Form S-1

Prospectus summary  
Company overview, page 1

1. Please balance your statement that you believe you have the first genetic medicine with the potential to significantly reduce the occurrence of seizures for Dravet syndrome patients and to address the severe intellectual and developmental disabilities of the disease by clarifying here that you are in an early stage of your development and that to date you have only conducted preclinical studies for your product candidate.

Edward Kaye  
Stoke Therapeutics, Inc.  
May 14, 2019  
Page 2  
Business  
STK-001: Preclinical data, page 100

2. Please disclose how many groups of pre-pubescent monkeys were administered with a single dose of STK-001 and how many control groups you used in the preclinical study described on page 103.  
Description of capital stock  
Anti-takeover provisions  
Restated certificate of incorporation and restated bylaw provisions, page 147

3. We continue to consider your response to our prior comment 8. Please note that we may have additional comments.  
Notes to Consolidated Financial Statements  
8. Convertible preferred stock  
Liquidation, page F-18, page F-18

4. Please demonstrate to us why you believe that common shareholders hold a majority of the board seats and, as such, that the company controls the vote of the Board of Directors and any deemed liquidation event. As of December 31, 2018, it appears that only two board seats elected are controlled by common shareholders. In this

regard, it appears that  
pursuant to articles 3.2.3 and 3.2.4 of your certificate of  
incorporation (exhibit 3.1) that  
the other four board seats elected are controlled by the preferred  
shareholders or  
effectively controlled by preferred shareholders voting together with  
common stock as a  
single class given the number of shares of preferred entitled to vote  
on an as-converted  
basis.

You may contact Rolf Sundwall at 202-551-3105 or Jim Rosenberg at  
202-551-3679 if  
you have questions regarding comments on the financial statements and related  
matters. Please  
contact Sonia Bednarowski at 202-551-3666 or Justin Dobbie at 202-551-3469 with  
any other  
questions.

FirstName LastNameEdward Kaye  
Comapany NameStoke Therapeutics, Inc.

Corporation Finance  
May 14, 2019 Page 2  
Healthcare & Insurance  
FirstName LastName

Sincerely,  
Division of  
Office of